Scoop: To fund Covid-19 nasal vaccine booster, Yale spinout snags Series A
A biotech working to create an intranasal vaccine booster for the ongoing Covid-19 pandemic has raised a Series A, the startup’s CEO confirmed to Endpoints News.
Known as Xanadu Bio, the company was spun out of Yale University. The raise will bankroll non-human primate studies for an intranasal spike mRNA vaccine booster, CEO and founder Bruce Turner told Endpoints via email.
A Dec. 27 SEC filing outlines a $30 million round for the Gladwyne, Pennsylvania biotech. Turner declined to discuss the funding or the names of the company’s investors, but said the company has “runway until late 2024.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.